详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

68| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究参与人：

研究单位： [1]Betta Pharmaceuticals Co., Ltd. [2]Cancer Hospital, Chinese Academy of Medical Science [3]Beijing Chaoyang Hospital,Beijing, Beijing, China, 100000 [4]Beijing Hospital,Beijing, Beijing, China, 100005 [5]Beijing Union Medical College Hospital,Beijing, Beijing, China, 100005 [6]Cancer Hospital, Chinese Academy of Medical Science,Beijing, Beijing, China, 100021 [7]China-japan friendship hospital in Beijing,Beijing, Beijing, China, 100029 [8]Peking University First Hospital,Beijing, Beijing, China, 100034 [9]Peking University People's Hospital,Beijing, Beijing, China, 100044 [10]304 Hospital of PLA,Beijing, Beijing, China, 100048 [11]Xuanwu Hospital, Capital Medical University,Beijing, Beijing, China, 100053 [12]People's Liberation Army General Hospital (301 Hospital),Beijing, Beijing, China, 100853 [13]Capital Medical University, Beijing Chest Hospital,Beijing, Beijing, China, 101149

研究目的：

The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.